Micreos

In this project recombinant anti-staphylococcal peptidoglycan hydrolases (PGH) are produced using an E. coli strain from the company Micreos Pharmaceuticals, a biotech specialized in developing precision antimicrobials for dermatology and derma-oncology, including Atopic Dermatitis (AD) and Cutaneous T-cell lymphoma (CTCL).

After growth of the recombinant E. coli strain in batch and fed-batch phase, the expression of the peptidoglycan hydrolase is induced by the addition of IPTG in fed-batch mode.

The main goals of this project are to implement successful fed-batch cultures and the development and optimization of a cell lysis step by sonication. Cell lysis is an essential first purification step to any recombinant protein expressed intracellularly. Sonication is used to break apart the cell wall, releasing intracellular and transmembrane proteins into solution for downstream purification.